Editor’s Note: Chris Goguen, Manager of Pharmacy Benefit Strategy for Medavie Blue Cross, took a deep dive into the major drug therapeutic categories that are impacting plans to uncover important trends and valuable insights for our stakeholders. This in-depth look at the data analytics and actionable insights is a must read. We invite advisors to share Chris’s key findings and recommendations with their clients for optimal plan management. We also encourage advisors and their clients to check out this Benefits Canada article in which Chris explains how leveraging data analytics and insights can drive smart, strategic decisions around their benefit plan offerings.
Targeted, high cost specialty medications will continue to drive new plan spending for the treatment of both common and rarer health conditions.
In the case of biologic drugs, one size does not fit all.
Cancer care has entered the workplace.
Mental health is the single largest challenge facing organizations today.
The health and economic consequences of diabetes cannot be ignored.
Connect with us: With over 75 years in the health insurance business and teams of in-house experts like Chris, we have lots of valuable information to share. Talk to your account executive to help you get the most out of your benefit plan.
For over 75 years, Medavie Blue Cross has been a leading health services partner for individuals, employers and governments across Canada. As the country’s leading Blue Cross plan with over one million card holders, we are a premier all-in-one carrier that provides health, dental, travel, life and disability benefits to...